• Explore /
  • Poster
  • / NRG-DT001 phase Ib trial of neoadjuvant navtemadlin (previously AMG232 and KRT232) concurrent with preoperative radiotherapy in wild-type p53 soft tissue sarcoma of the extremity and body wall.

NRG-DT001 phase Ib trial of neoadjuvant navtemadlin (previously AMG232 and KRT232) concurrent with preoperative radiotherapy in wild-type p53 soft tissue sarcoma of the extremity and body wall.

Abstract Poster

Authors

null

Meng Xu WELLIVER

The Ohio State University James Cancer Center, Columbus, OH

Meng Xu WELLIVER , Pedro A. Torres-Saavedra , Brian Andrew Van Tine , David G. Kirsch , Michelle A. Rudek , Paul Wakely , Gary K. Schwartz , Raphael E. Pollock , John Michael Kane III, Steve B. Jiang , Alan D. Rogers , Peter Houghton , Marta Batus , Andrea Lea Johnston , Matthew Spraker , Krisha Howell , Jonathan Harris , Dian Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NRG-DT001 NCT03217266

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 11521)

DOI

10.1200/JCO.2022.40.16_suppl.11521

Abstract #

11521

Poster Bd #

426

Abstract Disclosures

Similar Posters

First Author: Meng XU WELLIVER

First Author: Nai-Jung Chiang

First Author: Lee D. Cranmer

First Author: Dejan Juric